New findings from the DIRECT PLUS, 18-month-long lifestyle intervention trial underscores the potential to observe and signify alterations of MRI-assessed liver fat with proteomics according to new research from Ben-Gurion University of the Negev.
Treatment with lonafarnib boosted with ritonavir, with or without peginterferon alfa, resulted in significant virological and biochemical response in patients with chronic hepatitis D virus infection, according to data presented.
“As of yet, there is no FDA-approved therapy for this severe disease,” Ohad Etzion, MD, director of the department of gastroenterology and liver diseases at
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.